The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Open accessPublished version of a preprint
Abstract
BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Baricitinib, an inhibitor of JAK1 and JAK2, is reported to prevent COVID-19 severity followed by lowering IL-6 and TNFα levels (369).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [369]
Experimental — accuracy not yet measuredIn the citing paper
“In early clinical trials, the use of the JAK inhibitor baricitinib showed a reduction in serum levels of IL-6, IL-1β, and TNF (Bronte et al., 2020)”
From COVID-19 and the human innate immune system (2021) · cites this paper as Bronte et al., 2020
In the citing paper
“Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.102-105”
From Cytokine storm (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J. D., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S. R., Catton, M. C., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 993
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S. K., Bae, J. H., Kwon, H., & Nauck, M. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,061
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., Pellegrini, R. D. C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 764
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R. J., & Clercq, E. D. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 714
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 618
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 490
Mechanisms of long COVID and the path toward therapeutics
Peluso, M. J., & Deeks, S. G. (2024) · Cell · doi:10.1016/j.cell.2024.07.054 · Cited by 399
The state of complement in COVID-19
Afzali, B., Noris, M., Lambrecht, B. N., & Kemper, C. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00665-1 · Cited by 298
Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 263
The development of COVID-19 treatment
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125246 · Cited by 271
SARS‐CoV‐2 sensing by RIG‐I and MDA5 links epithelial infection to macrophage inflammation
Thorne, L., Reuschl, A., Zuliani‐Alvarez, L., Whelan, M. V. X., Turner, J. L. E., Noursadeghi, M., Jolly, C. L., & Towers, G. J. (2021) · The EMBO Journal · doi:10.15252/embj.2021107826 · Cited by 223
Hoang, T. N., Pino, M., Boddapati, A. K., Viox, E. G., Starke, C. E., Upadhyay, A. A., Gumber, S., Nekorchuk, M., Busman-Sahay, K., Strongin, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.007 · Cited by 212
Ely, E. W., Ramanan, A. V., Kartman, C. E., de Bono, S., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Saraiva, J. F. K., Chakladar, S., Marconi, V. C., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00006-6 · Cited by 194
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
Callender, L. A., Curran, M., Bates, S. M., Mairesse, M., Weigandt, J., & Betts, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01991 · Cited by 195
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
Keenan, C., Nichols, K. E., & Albeituni, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614704 · Cited by 179
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Satarker, S., Tom, A. A., Shaji, R. A., Alosious, A., Luvis, M., & Nampoothiri, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1855921 · Cited by 171
Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia
Taus, F., Salvagno, G. L., Canè, S., Fava, C., Mazzaferri, F., Carrara, E., Petrova, V., Barouni, R. M., Dima, F., Dalbeni, A., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315175 · Cited by 171
Self-citationDrug repurposing for COVID-19: Approaches, challenges and promising candidates
Ng, Y. L., Salim, C. K., & Chu, J. J. H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107930 · Cited by 158
Deciphering the state of immune silence in fatal COVID-19 patients
Bost, P., Sanctis, F. D., Canè, S., Ugel, S., Donadello, K., Castellucci, M., David, E., Fiore, A., Anselmi, C., Barouni, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21702-6 · Cited by 148
Self-citationThe infection risks of JAK inhibition
Adas, M. A., Alveyn, E., Cook, E., Dey, M., Galloway, J. B., & Bechman, K. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2014323 · Cited by 116
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 119
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
Cantini, F., Goletti, D., Petrone, L., Fard, S. N., Niccoli, L., & Foti, R. (2020) · Drugs · doi:10.1007/s40265-020-01421-w · Cited by 112
Tufan, Z. K., Kayaaslan, B., & Mer, M. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2108-239 · Cited by 111
Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials
Selvaraj, V., Finn, A., Lal, A., Khan, M. S., Dapaah-Afriyie, K., & Carino, G. P. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101489 · Cited by 101
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 124
Bower, H., Frisell, T., Giuseppe, D. D., Delcoigne, B., Ahlenius, G.-M., Baecklund, E., Chatzidionysiou, K., Feltelius, N., Forsblad‐d’Elia, H., Kastbom, A., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-219845 · Cited by 94
Ravaglia, C., Doglioni, C., Chilosi, M., Piciucchi, S., Dubini, A., Rossi, G., Pedica, F., Puglisi, S., Donati, L., Tomassetti, S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02411-2021 · Cited by 92
JAK inhibitors: Ten years after
Spinelli, F. R., Meylan, F., O’Shea, J. J., & Gadina, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202048922 · Cited by 91
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis
Chen, C., Wang, J., Li, H., Yuan, L.-T., Gale, R. P., & Liang, Y. (2021) · Leukemia · doi:10.1038/s41375-021-01266-6 · Cited by 87
COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?
Ombrello, M. J., & Schulert, G. S. (2021) · Translational research · doi:10.1016/j.trsl.2021.03.002 · Cited by 84
Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets
Hazeldine, J., & Lord, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680134 · Cited by 86
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
Zizzo, G., Tamburello, A., Castelnovo, L., Laria, A., Mumoli, N., Faggioli, P. M., Stefani, I., & Mazzone, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795315 · Cited by 78
Walz, L., Cohen, A. J., Rebaza, A. P., Vanchieri, J., Slade, M. D., Dela Cruz, C. S., & Sharma, L. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05730-z · Cited by 82
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
Bonam, S. R., Kotla, N. G., Bohara, R. A., Rochev, Y. A., Webster, T. J., & Bayry, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101051 · Cited by 76
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes
MacDonald, L., Alivernini, S., Tolusso, B., Elmesmari, A., Somma, D., Perniola, S., Paglionico, A., Petricca, L., Bosello, S. L., Carfì, A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147413 · Cited by 72
Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency
Magg, T., Okano, T., König, L. M., Boehmer, D. F. R., Schwartz, S. L., Inoue, K., Heimall, J. R., Licciardi, F., Ley‐Zaporozhan, J., Ferdman, R. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf9564 · Cited by 75
Levy, G., Guglielmelli, P., Langmuir, P. B., & Constantinescu, S. N. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002838 · Cited by 70
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Jiang, Y., Zhao, T., Zhou, X., Yu, X., Gutiérrez‐Castrellón, P., & Ma, X. (2022) · MedComm · doi:10.1002/mco2.154 · Cited by 77
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Assadiasl, S., Fatahi, Y., Mosharmovahed, B., Mohebbi, B., & Nicknam, M. H. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1874 · Cited by 66
Biswas, P., Hasan, M. M., Dey, D., Costa, A. C. D. S., Polash, S. A., Bibi, S., Ferdous, N., Kaium, M. A., Rahman, M. H., Jeet, F. K., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16096-3 · Cited by 65
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 64
Self-citationChilosi, M., Poletti, V. E., Ravaglia, C., Rossi, G., Dubini, A., Piciucchi, S., Pedica, F., Bronte, V., Pizzolo, G., Martignoni, G., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00808-8 · Cited by 62
Self-citation3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
SARS-CoV-2 Infection and Lung Regeneration
Zhao, F., Ma, Q., Yue, Q., & Chen, H. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00188-21 · Cited by 58
Agrawal, M., Brenner, E. J., Zhang, X., Modesto, I., Woolcott, J. C., Ungaro, R. C., Colombel, J., & Kappelman, M. D. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa303 · Cited by 56
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
Petrone, L., Petruccioli, E., Alonzi, T., Vanini, V., Cuzzi, G., Fard, S. N., Castilletti, C., Palmieri, F., Gualano, G., Vittozzi, P., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.02.023 · Cited by 58
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55
Park, J. K., Lee, E. B., Shin, K., Sung, Y., Kim, T., Kwon, S., Lee, M. S., Hong, S., Choi, B. Y., Lee, S., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e95 · Cited by 53
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
Saber-Ayad, M. M., Hammoudeh, S. M., Abu‐Gharbieh, E., Hamoudi, R., Tarazi, H., Al‐Tel, T. H., & Hamid, Q. A. (2021) · Pharmaceuticals · doi:10.3390/ph14070680 · Cited by 55
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling
Gajjela, B. K., & Zhou, M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.016 · Cited by 50
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Janus kinase inhibitors for the treatment of COVID-19
Kramer, A., Prinz, C., Fichtner, F., Fischer, A.-L., Thieme, V., Grundeis, F., Spagl, M., Seeber, C., Piechotta, V., Metzendorf, M., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015209 · Cited by 52
Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 50
Cuccarese, M. F., Earnshaw, B. A., Heiser, K., Fogelson, B., Davis, C. T., McLean, P., Gordon, H. B., Skelly, K.-R., Weathersby, F. L., Rodic, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.02.233064 · Cited by 48
Kumar, D., Rostad, C. A., Jaggi, P., Villacis-Nunez, D. S., Prince, C. Z., Lu, A., Hussaini, L., Nguyen, T. H., Malik, S., Ponder, L. A., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.028 · Cited by 47
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness
Pandharipande, P. P., Roberson, S. W., Harrison, F. E., Wilson, J. E., Bastarache, J. A., & Ely, E. W. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00238-2 · Cited by 46
Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic
Schvartz, A., Bélot, A., & Koné‐Paut, I. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.605807 · Cited by 47
Lin, Z., Niu, J., Xu, Y., Qin, L., Ding, J., & Zhou, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27482 · Cited by 46
Alunno, A., Najm, A., Mariette, X., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219725 · Cited by 45
Meyerowitz, E. A., Sen, P., Schoenfeld, S. R., Neilan, T. G., Frigault, M. J., Stone, J. H., Kim, A. Y., & Mansour, M. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1759 · Cited by 47
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Alexander, M. T., Luo, Y., Raimondi, G., O’Shea, J. J., & Gadina, M. (2021) · Pharmaceuticals · doi:10.3390/ph15010048 · Cited by 45
COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?
Jirjees, F., Saad, A. K., AlHano, Z., Hatahet, T., Al-Obaidi, H. J., & Bashi, Y. H. D. (2021) · Infectious Disease Reports · doi:10.3390/idr13020029 · Cited by 46
Salomão, R., Assis, V., Neto, I. V. D. S., Petriz, B. A., Babault, N., Durigan, J. L. Q., & Marqueti, R. D. C. (2023) · Biology · doi:10.3390/biology12060843 · Cited by 44
Gatti, M., Turrini, E., Raschi, E., Sestili, P., & Fimognari, C. (2021) · Pharmaceuticals · doi:10.3390/ph14080738 · Cited by 45
COVID-19: Diabetes Perspective—Pathophysiology and Management
Dallavalasa, S., Tulimilli, S. V., Janhavi, P., Ramachandra, R., Madhunapantula, S. V., & Veeranna, R. P. (2023) · Pathogens · doi:10.3390/pathogens12020184 · Cited by 45
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Limen, R. Y., Sedono, R., Sugiarto, A., & Hariyanto, T. I. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1982695 · Cited by 41
The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
Richardson, P. J., Robinson, B. W. S., Smith, D. P., & Stebbing, J. (2022) · Vaccines · doi:10.3390/vaccines10060951 · Cited by 44
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Current COVID-19 treatments: Rapid review of the literature
Dong, Y., Shamsuddin, A., Campbell, H. J., & Τheodoratou, E. (2021) · Journal of Global Health · doi:10.7189/jogh.11.10003 · Cited by 37
Pérez-Alba, E., Nuzzolo-Shihadeh, L., Aguirre-García, G. M., Espinosa-Mora, J. E., Lecona-Garcia, J. D., Flores-Pérez, R. O., Mendoza-Garza, M., & Camacho-Ortíz, A. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.05.009 · Cited by 37
JAK inhibition as a new treatment strategy for patients with COVID-19
Huang, J., Zhou, C., Jinniu, D., & Zhou, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115162 · Cited by 36
Blocking TNF signaling may save lives in COVID-19 infection
Ablamunits, V. G., & Lepsy, C. S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07166-x · Cited by 34
Upadhyay, A. A., Viox, E. G., Hoang, T. N., Boddapati, A. K., Pino, M., Lee, M. Y.-H., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37425-9 · Cited by 38
Chan, M., Vijay, S., McNevin, J. P., McElrath, M. J., Holland, E. C., & Gujral, T. S. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110426 · Cited by 33
Human cardiac organoids to model COVID‐19 cytokine storm induced cardiac injuries
Arhontoulis, D. C., Kerr, C. M., Richards, D., Tjen, K., Hyams, N. A., Jones, J. A., DeLeon‐Pennell, K. Y., Menick, D. R., Bräuninger, H., Lindner, D., et al. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3327 · Cited by 35
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?
Fialho, M. F. P., Brum, E. S., & Oliveira, S. M. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01160-w · Cited by 33
Tirelli, C., AMICI, M. D., Albrici, C., Mira, S., Nalesso, G., Re, B., Corsico, A. G., Mondoni, M., & Centanni, S. (2023) · Biology · doi:10.3390/biology12020177 · Cited by 35
COVID-19 illness and autoimmune diseases: recent insights
Li, J., Liu, H., Yin, X., Li, C., & Wang, J. (2021) · Inflammation Research · doi:10.1007/s00011-021-01446-1 · Cited by 33
Zhang, X., Shang, L.-H., Fan, G., Gu, X.-Y., Xu, J.-Y., Wang, Y.-M., Huang, L.-X., & Cao, B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.800492 · Cited by 28
COVID ‐19‐associated myositis may be dermatomyositis
Tanboon, J., & Nishino, I. (2020) · Muscle & Nerve · doi:10.1002/mus.27105 · Cited by 31
Patoulias, D., Doumas, M. N., Papadopoulos, C. E., & Karagiannis, A. I. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05884-4 · Cited by 32
First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
Chen, P., Datta, G., Li, Y. G., Chien, J. Y., Price, K., Chigutsa, E., Brown‐Augsburger, P., Poorbaugh, J., Fill, J. A., Benschop, R. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2405 · Cited by 31
Immune-Guided Therapy of COVID-19
Ferraccioli, G., Gremese, E., Goletti, D., Petrone, L., Cantini, F., Ugel, S., Canè, S., & Bronte, V. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0675 · Cited by 30
Self-citationRoles of cytokine storm in sepsis progression: biomarkers, and emerging therapeutic strategies
You, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1696366 · Cited by 31
Ali, F. E. M., Mohammedsaleh, Z. M., Ali, M., & Ghogar, O. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i15.1531 · Cited by 29
Baricitinib reduces 30‐day mortality in older adults with moderate‐to‐severe COVID ‐19 pneumonia
Abizanda, P., Mayo, J. M. C., Romero, M. M., Zamora, E. B. C., Sahuquillo, M. T. T., Rizos, L. R., Sánchez‐Jurado, P. M., Nievas, G. S., Escolano, C. C., Serrano, A. O., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17357 · Cited by 29
Covid-19 interface with drug misuse and substance use disorders
Cisneros, I. E., & Cunningham, K. A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108766 · Cited by 30
Network analytics for drug repurposing in COVID-19
Siminea, N., Popescu, V., Martín, J. Á. S., Florea, D., Gavril, G., Gheorghe, A.-M., Iţcuş, C., Kanhaiya, K., Pacioglu, O., Popa, L. I., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab490 · Cited by 30
Akbarzadeh-Khiavi, M., Torabi, M., Rahbarnia, L., & Safary, A. (2021) · Infection · doi:10.1007/s15010-021-01730-6 · Cited by 27
Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review
Smail, S. W., Saeed, M., Alkasalias, T., Khudhur, Z. O., Younus, D. A., Rajab, M. F., Abdulahad, W. H., Hussain, H. I., Niaz, K., & Safdar, M. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112087 · Cited by 26
Ngamprasertchai, T., Kajeekul, R., Sivakorn, C., Ruenroengbun, N., Luvira, V., Siripoon, T., & Luangasanatip, N. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00545-0 · Cited by 25
Khaledi, M., Sameni, F., Yahyazade, S., Radandish, M., Owlia, P., Bagheri, N., Afkhami, H., Mahjoor, M., Esmaelpour, Z., Kohansal, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.961027 · Cited by 25
Additional baricitinib loading dose improves clinical outcome in COVID-19
Hasan, M. J., Rabbani, R., Anam, A. M., & Huq, S. M. R. (2020) · Open Medicine · doi:10.1515/med-2021-0010 · Cited by 24
COVID-19: the new challenge for rheumatologists. One year later
Puxeddu, I., Ferro, F., Bartoloni, E., Elefante, E., Baldini, C., Scirè, C. A., Talarico, R., Migliorini, P., Mosca, M., & Bombardieri, S. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/si106e · Cited by 26
Wang, H., Zhang, J., Lu, Z., Dai, W., Ma, C., Xiang, Y., & Zhang, Y. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab373 · Cited by 23
Metadata
- Authors
- Bronte, V., Ugel, S., Tinazzi, E., Vella, A., De Sanctis, F., Canè, S., Batani, V., Trovato, R., Fiore, A., Petrova, V., Hofer, F., Barouni, R. M., Musiu, C., Caligola, S., Pinton, L., Torroni, L., Polati, E., Donadello, K., Friso, S., Pizzolo, F., Iezzi, M., Facciotti, F., Pelicci, P. G., Righetti, D., Bazzoni, P., Rampudda, M., Comel, A., Mosaner, W., Lunardi, C., & Olivieri, O.
- Affiliations
- University of Verona (IT)
- European Institute of Oncology (IT)
- Ospedale P. Pederzoli – Casa di Cura Privata S.p.a. (IT)
- Corresponding author
- Bronte, Vincenzo
- ORCID
- Bronte, Vincenzo
- Ugel, Stefano
- Tinazzi, Elisa
- Vella, Antonio
- Canè, Stefania
- Batani, Veronica
- Trovato, Rosalinda
- Fiore, Alessandra
- Petrova, Varvara
- Hofer, Francesca
- Barouni, Roza Maria
- Musiu, Chiara
- Caligola, Simone
- Pinton, Laura
- Torroni, Lorena
- Polati, Enrico
- Donadello, Katia
- Friso, Simonetta
- Pizzolo, Francesca
- Iezzi, Manuela
- Facciotti, Federica
- Pelicci, Pier Giuseppe
- Lunardi, Claudio
- Olivieri, Oliviero
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-03
- Volume
- 130
- Issue
- 12
- Pages
- 6409-6416
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8016181
- OpenAlex
- W3037867966
- Cited by
- 281
- References
- 23
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 23 · 2023: 39 · 2022: 72 · 2021: 89 · 2020: 23
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Fondazione Cariverona Italy (ENACT)
- Fondazione TIM Italy (IMMUNOVID)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- baricitinib, COVID-19 pandemic, SARS-CoV-2, JAK/STAT signaling, STAT3 phosphorylation, cytokine storm, interleukin-6, IL-1β, TNF-α, lymphopenia, T cell reconstitution, B cell recovery, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Aged, 80 and over, Azetidines, B-Lymphocytes, Female, Humans, Longitudinal Studies, Male, Middle Aged, Purines, Pyrazoles, Severity of Illness Index, Sulfonamides, T-Lymphocytes, Cytokines, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
